J W In1, H Park1, E Y Rho1, S Shin1, K U Park1, M H Park1, E Y Song2. 1. Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, South Korea. 2. Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, South Korea; Medical Research Center, Seoul National University College of Medicine, Seoul, South Korea. Electronic address: eysong1@snu.ac.kr.
Abstract
INTRODUCTION: Angiotensin II is a peptide hormone involved in the renin-angiotensin system (RAS). Anti-angiotensin receptor 1 (AT1R) antibodies are implicated in stimulating RAS and are suspected to have some adverse impacts on renal transplantation outcome. METHODS: From November 2009 to February 2012, 37 remaining sera from renal transplantation recipients with biopsy-proven antibody-mediated rejection (AMR) (n = 6), acute cellular rejection (ACR) (n = 23), and AMR + ACR (n = 8) without preformed human leukocyte antigeon (HLA) antibodies were tested with anti-AT1R antibody assay. Forty-two control patients without rejection also were analyzed. RESULTS: The frequency of elevated anti-AT1R antibodies was higher in patients with AMR (n = 14) compared to controls (28.6% vs 4.9%, P = .03, OR = 8.0). It was also higher in patients with AMR + ACR (n=8) (37.5% vs 4.9%, P = .03, OR = 12.0). There was no difference in frequencies of elevated anti-AT1R antibody in patients with ACR. CONCLUSION: Anti-AT1R antibodies were suspected to be associated with occurrence of AMR without preformed HLA antibodies in renal transplantation. Further studies in a larger number of patients are needed.
INTRODUCTION:Angiotensin II is a peptide hormone involved in the renin-angiotensin system (RAS). Anti-angiotensin receptor 1 (AT1R) antibodies are implicated in stimulating RAS and are suspected to have some adverse impacts on renal transplantation outcome. METHODS: From November 2009 to February 2012, 37 remaining sera from renal transplantation recipients with biopsy-proven antibody-mediated rejection (AMR) (n = 6), acute cellular rejection (ACR) (n = 23), and AMR + ACR (n = 8) without preformed human leukocyte antigeon (HLA) antibodies were tested with anti-AT1R antibody assay. Forty-two control patients without rejection also were analyzed. RESULTS: The frequency of elevated anti-AT1R antibodies was higher in patients with AMR (n = 14) compared to controls (28.6% vs 4.9%, P = .03, OR = 8.0). It was also higher in patients with AMR + ACR (n=8) (37.5% vs 4.9%, P = .03, OR = 12.0). There was no difference in frequencies of elevated anti-AT1R antibody in patients with ACR. CONCLUSION: Anti-AT1R antibodies were suspected to be associated with occurrence of AMR without preformed HLA antibodies in renal transplantation. Further studies in a larger number of patients are needed.
Authors: Meghan H Pearl; Qiuheng Zhang; Miguel Fernando Palma Diaz; Jonathan Grotts; Maura Rossetti; David Elashoff; David W Gjertson; Patricia Weng; Elaine F Reed; Eileen Tsai Chambers Journal: Kidney Int Date: 2017-09-18 Impact factor: 10.612
Authors: Jian Zhang; Mingxu Wang; Jun Liang; Ming Zhang; Xiao-Hong Liu; Le Ma Journal: Int J Environ Res Public Health Date: 2017-05-09 Impact factor: 3.390
Authors: Meghan H Pearl; Jonathan Grotts; Maura Rossetti; Qiuheng Zhang; David W Gjertson; Patricia Weng; David Elashoff; Elaine F Reed; Eileen Tsai Chambers Journal: Kidney Int Rep Date: 2018-12-21